Leptomeningeal Spread in Glioblastoma: Diagnostic and Therapeutic Challenges.
Diagnostic
Glioblastoma
Leptomeningeal spread
Treatment
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
31
03
2020
accepted:
26
06
2020
entrez:
4
1
2021
pubmed:
5
1
2021
medline:
22
6
2021
Statut:
ppublish
Résumé
Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor. Leptomeningeal spread (LMS) is a severe complication of GBM, raising diagnostic and therapeutic challenges in clinical routine. We performed a review of the literature focused on LMS in GBM. MEDLINE and EMBASE databases were queried from 1989 to 2019 for articles describing diagnosis and therapeutic options in GBM LMS, as well as risk factors and pathogenic mechanisms. We retrieved 155 articles, including retrospective series, case reports, and early phase clinical trials, as well as preclinical studies. These articles confirmed that LMS in GBM remains (a) a diagnostic challenge with cytological proof of LMS obtained in only 35% of cases and (b) a therapeutic challenge with a median overall survival below 2 months with best supportive care alone. For patients faced with suggestive clinical symptoms, whole neuroaxis magnetic resonance imaging and cerebrospinal fluid analysis are both recommended. Liquid biopsies are under investigation and may help prompt a reliable diagnosis. Based on the literature, a multimodal and personalized therapeutic approach of LMS, including surgery, radiotherapy, systemic cytotoxic chemotherapy, and intrathecal chemotherapies, may provide benefits to selected patients. Interestingly, molecular targeted therapies appear promising in case of actionable molecular target and should be considered. As the prognosis of glioblastoma is improving over time, LMS becomes a more common complication. Our review highlights the need for translational studies and clinical trials dedicated to this challenging condition in order to improve diagnostic and therapeutic strategies. This review summarizes the diagnostic tools and applied treatments for leptomeningeal spread, a complication of glioblastoma, as well as their outcomes. The importance of exhaustive molecular testing for molecular targeted therapies is discussed. New diagnostic and therapeutic strategies are outlined, and the need for translational studies and clinical trials dedicated to this challenging condition is highlighted.
Sections du résumé
BACKGROUND
Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor. Leptomeningeal spread (LMS) is a severe complication of GBM, raising diagnostic and therapeutic challenges in clinical routine.
METHODS
We performed a review of the literature focused on LMS in GBM. MEDLINE and EMBASE databases were queried from 1989 to 2019 for articles describing diagnosis and therapeutic options in GBM LMS, as well as risk factors and pathogenic mechanisms.
RESULTS
We retrieved 155 articles, including retrospective series, case reports, and early phase clinical trials, as well as preclinical studies. These articles confirmed that LMS in GBM remains (a) a diagnostic challenge with cytological proof of LMS obtained in only 35% of cases and (b) a therapeutic challenge with a median overall survival below 2 months with best supportive care alone. For patients faced with suggestive clinical symptoms, whole neuroaxis magnetic resonance imaging and cerebrospinal fluid analysis are both recommended. Liquid biopsies are under investigation and may help prompt a reliable diagnosis. Based on the literature, a multimodal and personalized therapeutic approach of LMS, including surgery, radiotherapy, systemic cytotoxic chemotherapy, and intrathecal chemotherapies, may provide benefits to selected patients. Interestingly, molecular targeted therapies appear promising in case of actionable molecular target and should be considered.
CONCLUSION
As the prognosis of glioblastoma is improving over time, LMS becomes a more common complication. Our review highlights the need for translational studies and clinical trials dedicated to this challenging condition in order to improve diagnostic and therapeutic strategies.
IMPLICATIONS FOR PRACTICE
This review summarizes the diagnostic tools and applied treatments for leptomeningeal spread, a complication of glioblastoma, as well as their outcomes. The importance of exhaustive molecular testing for molecular targeted therapies is discussed. New diagnostic and therapeutic strategies are outlined, and the need for translational studies and clinical trials dedicated to this challenging condition is highlighted.
Identifiants
pubmed: 33394574
doi: 10.1634/theoncologist.2020-0258
pmc: PMC7648332
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1763-e1776Informations de copyright
© AlphaMed Press 2020.
Références
Neurosurgery. 2019 Nov 1;85(5):E924-E932
pubmed: 31058968
Acta Neuropathol Commun. 2019 Jul 25;7(1):119
pubmed: 31345255
Int J Cancer. 2019 Mar 15;144(6):1331-1344
pubmed: 30414187
J Neurooncol. 1999 Sep;44(2):163-8
pubmed: 10619500
J Neurosurg. 1989 Feb;70(2):240-8
pubmed: 2783608
Neuro Oncol. 2002 Apr;4(2):129-33
pubmed: 11916505
JAMA Oncol. 2017 Aug 1;3(8):1094-1101
pubmed: 28426845
Neurology. 2004 Aug 10;63(3):E8
pubmed: 15304620
Clin Transl Immunology. 2019 May 20;8(5):e1050
pubmed: 31139410
In Vivo. 2011 Nov-Dec;25(6):991-3
pubmed: 22021694
Neurooncol Pract. 2016 Dec;3(4):268-271
pubmed: 31386052
Neurosurgery. 1992 Jan;30(1):64-71
pubmed: 1738457
Neurology. 2013 Apr 23;80(17):1598-605; discussion 1603
pubmed: 23553479
J Neurosci. 1998 Apr 1;18(7):2370-6
pubmed: 9502798
Clin Cancer Res. 2006 Feb 15;12(4):1349-54
pubmed: 16489093
Radiol Case Rep. 2019 Mar 09;14(5):613-617
pubmed: 30906492
J Neurooncol. 2019 Jan;141(2):337-345
pubmed: 30414100
Neurosurgery. 1998 Mar;42(3):599-607; discussion 607-8
pubmed: 9526994
AME Case Rep. 2018 May 22;2:26
pubmed: 30264022
N Engl J Med. 2016 Dec 29;375(26):2561-9
pubmed: 28029927
Neurosurg Rev. 2010 Jul;33(3):375-81; discussion 381
pubmed: 20306105
J Neurooncol. 2014 Dec;120(3):597-605
pubmed: 25168214
Radiology. 2000 Oct;217(1):50-3
pubmed: 11012422
Neuropathol Appl Neurobiol. 2014 Apr;40(3):327-36
pubmed: 24127995
Neurosurgery. 2018 Dec 1;83(6):1119-1127
pubmed: 29790976
Neurology. 2019 May 21;92(21):e2483-e2491
pubmed: 31019097
J Mol Diagn. 2017 Jan;19(1):24-34
pubmed: 27863260
Oncol Rep. 2017 Dec;38(6):3291-3296
pubmed: 29039591
J Clin Neurosci. 2018 Apr;50:172-176
pubmed: 29396060
Neurosurgery. 2011 Aug;69(2):399-410; discussion 410-1
pubmed: 21415790
Clin Neurol Neurosurg. 2014 May;120:27-31
pubmed: 24731571
Clin Neurol Neurosurg. 2011 Jun;113(5):407-10
pubmed: 21208740
Neurol Med Chir (Tokyo). 2014;54(4):302-9
pubmed: 24390189
Oncol Lett. 2018 May;15(5):6641-6647
pubmed: 29616127
J Clin Neurosci. 2012 Nov;19(11):1511-5
pubmed: 22595352
Sci Rep. 2015 Dec 04;5:17758
pubmed: 26635136
Anticancer Res. 2019 Feb;39(2):1035-1041
pubmed: 30711992
Surg Neurol. 1991 May;35(5):377-80
pubmed: 1851338
Medicine (Baltimore). 2017 Jul;96(27):e7422
pubmed: 28682902
Ann Neurol. 1980 Dec;8(6):605-8
pubmed: 6260012
BMC Res Notes. 2014 Aug 07;7:496
pubmed: 25099491
Lancet. 2012 May 26;379(9830):1984-96
pubmed: 22510398
J Neurooncol. 2014 May;118(1):9-18
pubmed: 24557958
Clin Neurol Neurosurg. 2003 Dec;106(1):9-15
pubmed: 14643909
Oncotarget. 2019 Jun 04;10(38):3818-3826
pubmed: 31217909
Nat Rev Genet. 2019 Feb;20(2):71-88
pubmed: 30410101
Cancer Cytopathol. 2015 Feb;123(2):123-35
pubmed: 25487367
J Neurosurg. 1994 Mar;80(3):515-9
pubmed: 8113864
Front Neurol. 2014 Nov 03;5:220
pubmed: 25404928
Neurosurgery. 2003 Feb;52(2):324-29; discussion 330
pubmed: 12535360
Surg Neurol. 2006 May;65(5):472-7; discussion 477
pubmed: 16630907
Yonsei Med J. 2000 Aug;41(4):517-21
pubmed: 10992815
J Clin Oncol. 2009 Mar 10;27(8):1275-9
pubmed: 19188675
Oncogene. 2018 Feb 8;37(6):777-786
pubmed: 29059154
Acta Neurochir (Wien). 2018 May;160(5):1073-1077
pubmed: 29532260
J Neurooncol. 2014 Sep;119(2):361-8
pubmed: 24942463
Surg Neurol. 2002 Jan;57(1):46-8
pubmed: 11834277
Cancers (Basel). 2019 Jun 08;11(6):
pubmed: 31181803
Acta Neurochir (Wien). 2015 Apr;157(4):569-76
pubmed: 25663100
Brain Tumor Res Treat. 2019 Apr;7(1):39-43
pubmed: 31062530
Acta Neurochir (Wien). 1994;126(2-4):84-92
pubmed: 8042560
J Craniovertebr Junction Spine. 2010 Jul;1(2):126-9
pubmed: 21572635
Cancer. 1989 May 15;63(10):2014-23
pubmed: 2539242
Neurol Med Chir (Tokyo). 2013;53(7):474-81
pubmed: 23883558
Neurosurgery. 1996 Aug;39(2):235-50; discussion 250-2
pubmed: 8832660
Ann Oncol. 2019 Feb 1;30(2):211-218
pubmed: 30576421
Brain Pathol. 2009 Jan;19(1):81-90
pubmed: 18452568
Acta Neuropathol Commun. 2019 Apr 29;7(1):66
pubmed: 31036078
J Neurooncol. 2003 Feb;61(3):227-35
pubmed: 12675316
Neurology. 2015 Aug 18;85(7):e57-61
pubmed: 26283762
Cancer Chemother Pharmacol. 1989;23(5):301-7
pubmed: 2706735
Surg Neurol Int. 2014 Mar 27;5:40
pubmed: 24818047
J Oncol. 2019 Jul 29;2019:1740763
pubmed: 31467533
Oncol Lett. 2015 Apr;9(4):1885-1888
pubmed: 25789061
Clin Neurol Neurosurg. 2000 Dec;102(4):223-226
pubmed: 11154809
Cancer Lett. 2010 May 28;291(2):256-62
pubmed: 19945214
J Neurooncol. 2016 Feb;126(3):385-93
pubmed: 26384810
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86
pubmed: 30445539
Int J Neurosci. 2012 Nov;122(11):691-4
pubmed: 22720749
Acta Neurol Scand. 1989 Feb;79(2):133-9
pubmed: 2711819
J Neurooncol. 2016 May;127(3):581-7
pubmed: 26830090
J Neurooncol. 2001 May;53(1):21-6
pubmed: 11678426
Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):886-93
pubmed: 25220720
J Clin Neurosci. 2004 Jan;11(1):37-41
pubmed: 14642363
Acta Inform Med. 2014 Apr;22(2):142-4
pubmed: 24825943
Br J Cancer. 2000 Jan;82(1):52-5
pubmed: 10638966
Front Neurol. 2018 Mar 21;9:127
pubmed: 29619003
Neuro Oncol. 2013 Jan;15(1):91-6
pubmed: 23095230
Ann Clin Transl Neurol. 2014 Jan;1(1):45-8
pubmed: 25356380
Clin Nucl Med. 2018 Jul;43(7):518-519
pubmed: 29742608
J Neurooncol. 2011 Dec;105(3):555-62
pubmed: 21643841
J Clin Neurosci. 2005 Sep;12(7):834-7
pubmed: 16198924
Neuro Oncol. 2010 Mar;12(3):233-42
pubmed: 20167811
J Neurosurg. 1994 May;80(5):834-9
pubmed: 8169622
J Neurooncol. 2018 Feb;136(3):555-563
pubmed: 29196927
Clin Cancer Res. 1996 Jun;2(6):963-72
pubmed: 9816257
J Clin Neurosci. 2011 Aug;18(8):1133-5
pubmed: 21658953
Neuro Oncol. 2019 May 6;21(5):648-658
pubmed: 30715514
Cancer Discov. 2016 Nov;6(11):1230-1236
pubmed: 27683556
J Neurol Sci. 2017 Oct 15;381:315-317
pubmed: 28991705
Cancer. 1999 Oct 1;86(7):1347-53
pubmed: 10506724
Neurol India. 2006 Dec;54(4):428-30
pubmed: 17114859
Anticancer Drugs. 2012 Jul;23(6):659-65
pubmed: 22634799
Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1392
pubmed: 21394504
Acta Neurochir (Wien). 2001;143(1):25-9
pubmed: 11345714
Neurol Res. 2009 Jun;31(5):453-62
pubmed: 19309540
Neurosurgery. 1990 Oct;27(4):516-21; discussion 521-2
pubmed: 2172859
Am J Health Syst Pharm. 2006 Nov 1;63(21):2083-6
pubmed: 17057045
Nature. 2019 Jan;565(7741):654-658
pubmed: 30675060
Neurosurgery. 2017 Mar 1;80(3):421-430
pubmed: 27218235
Int J Surg Oncol. 2011;2011:769753
pubmed: 22312523
Sci Transl Med. 2017 Jul 19;9(399):
pubmed: 28724573
J Clin Neurosci. 2002 Nov;9(6):725-8
pubmed: 12604298
Curr Oncol Rep. 2018 Jun 6;20(8):60
pubmed: 29876874
World Neurosurg. 2018 Feb;110:345-348
pubmed: 29066318
J Neurooncol. 2012 Nov;110(2):221-6
pubmed: 22886532
PLoS One. 2016 Jun 02;11(6):e0155315
pubmed: 27253224
Cureus. 2019 Apr 9;11(4):e4416
pubmed: 31245204
J Neurooncol. 2003 Jun;63(2):191-9
pubmed: 12825824
Am J Clin Pathol. 2007 Apr;127(4):585-90
pubmed: 17369134
Asia Pac J Clin Oncol. 2018 Oct;14(5):e366-e373
pubmed: 29473335
Drug Des Devel Ther. 2017 Jun 26;11:1905-1915
pubmed: 28721010
Surg Neurol Int. 2016 Oct 20;7:92
pubmed: 27857856
Clin Neurol Neurosurg. 2009 May;111(4):390-4
pubmed: 19128871
Front Oncol. 2018 Nov 20;8:509
pubmed: 30524956
Surg Neurol. 2001 Jul;56(1):33-7; discussion 37-8
pubmed: 11546569
Mol Brain. 2019 May 6;12(1):45
pubmed: 31060588
Surg Neurol Int. 2017 Oct 10;8:243
pubmed: 29119041
Future Sci OA. 2017 Mar 24;3(3):FSO189
pubmed: 28883992
Oncologist. 2011;16(8):1175-88
pubmed: 21795431
Tumori. 2008 Nov-Dec;94(6):877-81
pubmed: 19267111
J Korean Neurosurg Soc. 2011 Jun;49(6):334-8
pubmed: 21887390
Fluids Barriers CNS. 2018 Jun 4;15(1):16
pubmed: 29860942
Asian J Surg. 2017 Jan;40(1):61-65
pubmed: 23978432
Cells. 2019 Sep 30;8(10):
pubmed: 31574953
J Neurol Sci. 2019 Aug 15;403:19-23
pubmed: 31176194
J Neurooncol. 2011 Jan;101(2):329-33
pubmed: 20549302
J Neurosurg. 2013 Aug;119(2):412-9
pubmed: 23641829
J Cancer Res Ther. 2015 Oct-Dec;11(4):1039
pubmed: 26881656
Oncotarget. 2017 Oct 24;8(61):103890-103899
pubmed: 29262608
Clin Cancer Res. 1999 Nov;5(11):3394-402
pubmed: 10589750
World Neurosurg. 2018 Dec;120:442-447
pubmed: 30253992
J Neurooncol. 2008 May;87(3):309-16
pubmed: 18074105
J Clin Neurosci. 2017 Jun;40:115-119
pubmed: 28246006
Oncotarget. 2016 Aug 9;7(32):52423-52435
pubmed: 27244880
Neuro Oncol. 2019 May 6;21(5):571-584
pubmed: 30668804
J Neurooncol. 2006 Sep;79(3):307-14
pubmed: 16645719
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Neurosurgery. 1989 Oct;25(4):533-40
pubmed: 2797391
Am J Phys Med Rehabil. 2014 Sep;93(9):838-9
pubmed: 25140830
Front Oncol. 2017 Jun 16;7:120
pubmed: 28670569
Lancet Oncol. 2017 Jun;18(6):e330-e340
pubmed: 28593859
J Clin Neurosci. 2019 Mar;61:277-278
pubmed: 30472340